Avella Specialty Pharmacy names new CEO
PHOENIX — Avella Specialty Pharmacy on Thursday named Rebecca Shanahan CEO. Shanahan brings more than two decades of successful leadership experience in the healthcare sector, as well as five years of service on Avella’s board of directors, to her new role.
Shanahan will succeed John Musil in that capacity, though Musil will continue to actively serve as chairman, Avella stated, focusing on long-term strategy and serving as the company’s ambassador to the clinical community.
“Avella has increased its revenue more than five-fold organically in the past five years and grown its operations correspondingly," Musil stated. "To fully capitalize on the opportunities resulting from our success and scale, Avella is fortunate to have Rebecca Shanahan taking on the role of chief executive officer. Not only does she bring a depth and breadth of healthcare, health plan and specialty pharmacy expertise that will be instrumental to Avella’s ongoing growth, but she already has a strong understanding of our organization through her years of participation on the board of directors.”
Shanahan’s healthcare experience spans the provider sector. Earlier in her career, she served in executive roles at three health systems: as SVP business development for the University of Chicago Hospitals and Faculty Practice Plan; as SVP Methodist Medical Group and Ambulatory Services; and as general counsel of Community Hospitals of Indiana.
From 1997 to 2005, Shanahan served as a board member, general counsel and EVP strategic initiatives for Priority Healthcare. From 2005 to 2007, Shanahan served as EVP and head of the Aetna Specialty Pharmacy. Since that time, she has provided consulting services to leading healthcare companies, including Cardinal Health, Shoppers Drug Mart, Bayer Pharmaceuticals, Bristol Myers Squibb, Rite Aid and Cancer Centers of Excellence.
“I am honored to be joining Avella at this exciting time,” Shanahan said. “The company has long been a leader and innovator in the development of unique specialty pharmacy services, with many well-deserved ‘best in class’ recognitions. I am excited about the opportunity to work with John, the board of directors, and the entire Avella team to continue to expand our clinical pharmacy, patient advocacy, and specialty pharmacy services into new disease categories and via new healthcare partnerships.”
Mylan tapped as Gilead’s exclusive business partner for India
PITTSBURGH and MUMBAI, India — Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences’ branded medicines business partner for India.
Under this exclusive agreement, Mylan will market and distribute in India the following drugs from Gilead:
- HIV therapies Viread (tenofovir disoproxil fumarate), Truvada (emtricitabine/tenofovir disoproxil fumarate) and the newer single-tablet regiment Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg);
- AmBisome (amphotericin B liposome for injection), used to treat life-threatening, systemic fungal infections. It’s also used to treat the parasitic disease visceral leishmaniasis; and
- Viread for its use as a treatment for chronic hepatitis B virus (HBV) infection.
"This further extension of our collaboration with Gilead builds off of our existing successful partnership manufacturing and supplying high-quality, cost-effective generic antiretroviral therapy for those in resource challenged countries, delivering on our mission of providing access to high quality medicine to the world’s seven billion people," Mylan CEO Heather Bresch said.
Mylan was selected in September 2012 as a leading supplier of antiretroviral medication to India’s National AIDS Control Organization. India is home to the world’s largest-population of people with HIV/AIDS, with approximately 2.4 million people living with the disease.
Indiana Senate passes generic biologic pathway legislation
WASHINGTON — The Biotechnology Industry Organization and the Indiana Health Industry Forum on Thursday commended the Indiana Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
The policies outlined in the identical SB 262 align with BIO’s principles on biologic substitution, therefore BIO and IHIF support passage of this bill as it moves along for consideration by the Indiana House of Representatives.
Although similar bills have been addressed in other states, SB 262 enjoys the support of a broad coalition of both biologic and biosimilar manufacturing companies. This bill includes transparent communication on all biologic medicines dispensed in order to maintain a consistent and complete medical record. This legislation represents a significant step forward and ensures transparency and communication between patients and their treatment teams.
While the Food and Drug Administration oversees approval of biologic medicines and designation of interchangeability, policies governing whether one product may be substituted in place of a doctor’s prescription and whether a pharmacist must inform patients and doctors are covered by state law. SB 262 seeks to properly preserve patient access to accurate prescription information, maintain incentives for innovation and promote a competitive market for biologic therapies.
Bills such as this that properly address the important aspect of physician communication represent model legislation necessary in all 50 states to address this cutting-edge technology, BIO said.
The FDA currently is developing a pathway for the development and approval of safe and effective interchangeable biologic products in the United States. However, there is still a major role for states to play in ensuring substitution practices remain transparent and physicians remain engaged in the process, BIO noted.